Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The "Hoddle Muddle": using faith healers and other complementary therapists in sports medicine.

British journal of sports medicine·1998
Same author

The rise and fall of complementary medicine.

Journal of the Royal Society of Medicine·1998
Same author

The prevalence of complementary/alternative medicine in cancer: a systematic review.

Cancer·1998
Same author

Does moderate alcohol consumption affect fertility? Follow up study among couples planning first pregnancy.

BMJ (Clinical research ed.)·1998
Same author

[Phytotherapy. 1. Use in diseases of the locomotor system].

Fortschritte der Medizin·1998
Same author

[Phytotherapy. 5: Gastrointestinal tract (2)].

Fortschritte der Medizin·1998

Related Experiment Video

Updated: May 16, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Plants with hypoglycemic activity in humans.

E Ernst1

  • 1Department of Complementary Medicine, Postgraduate Medical School, University of Exeter, Exeter, U.K.

Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|December 1, 2012
PubMed
Summary

Clinical trials show limited evidence for plant-based glucose-lowering remedies. Despite many plants having suspected potential, rigorous studies are lacking to confirm their effectiveness for managing blood sugar levels.

Area of Science:

  • Phytomedicine
  • Clinical Pharmacology
  • Evidence-Based Medicine

Background:

  • Over 400 plant species are recognized for potential glucose-lowering effects.
  • Current evidence often relies on traditional use or animal studies, lacking clinical validation.

Purpose of the Study:

  • To review direct clinical trial evidence on the efficacy of plant-based remedies for glucose lowering.
  • To assess the quality of evidence supporting the use of hypoglycemic plant remedies.

Main Methods:

  • Systematic literature search for clinical trials on glucose-lowering plants.
  • Analysis of study designs, methodological quality, and reported outcomes.

Main Results:

  • 22 clinical studies were identified, with most reporting positive effects.

Related Experiment Videos

Last Updated: May 16, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

  • The majority of studies exhibited poor methodological quality.
  • Only five randomized controlled trials were found, with inconclusive results.

    • Conclusions:

    • Current clinical trial data do not robustly support the use of hypoglycemic plant remedies.
    • Further high-quality research is necessary to establish the clinical utility of these botanical agents.